Blinatumomab was active across age and risk groups in patients with relapsed or refractory BCP–ALL.
Published OnlineFirst October 14, 2016
Thank you for sharing this Cancer Discovery article.
NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.